Atea Pharmaceuticals (AVIR) Retained Earnings (2019 - 2026)

Atea Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at $801.7 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 679336.44% year-over-year to $801.7 million; the TTM figure through Mar 2026 stood at $801.7 million (up 679336.44% YoY), while the FY2025 annual figure was $797.8 million, up 319.03% from the prior year.
• Retained Earnings for Q1 2026 stood at $801.7 million, roughly flat from $797.8 million in the prior quarter.
• The five-year high for Retained Earnings was $801.7 million in Q1 2026, with the low at -$477.7 million in Q3 2025.
• The 5-year median for Retained Earnings is $14.0 million (2022), against an average of $275.5 million.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings plunged 74624.49% in 2025, then surged 679336.44% in 2026.
• Atea Pharmaceuticals' Retained Earnings stood at -$59.9 million in 2022, then surged by 1353.76% to $750.7 million in 2023, then slumped by 148.51% to -$364.2 million in 2024, then surged by 319.03% to $797.8 million in 2025, then gained by 0.5% to $801.7 million in 2026.
• Business Quant data shows AVIR's Retained Earnings at $801.7 million in Q1 2026, $797.8 million in Q4 2025, and -$477.7 million in Q3 2025.